Monthly Archives

August 2017

$4 Million Animal Health Investment Means More Strides for Treating Diabetic Pets

By | News & Media

Werth Family Investment Associates backs Likarda’s proprietary Kanslet™ diabetes treatment in dogs and cats.


KANSAS CITY, Kan. – Cutting-edge biotech research laboratory, Likarda, has received $4,000,000 in Series A funding from Werth Family Investment Associates, bringing the promise of future diabetes treatment options to dogs and cats.

Likarda is the leading regenerative medicine company for companion animals. They have discovered—and are commercializing—a better way to manage diabetes in dogs and cats. Their insulin-producing cell clusters, called the Kanslet™, can be infused into animals with diabetes. The process allows veterinarians to offer a minimally invasive, cost-effective answer to pet owners battling the burden of diabetes in dogs and cats.

Read More

Likarda Outgrows Space at KU Incubator

By | News & Media

Biotech research lab continues promising growth with move.


KANSAS CITY, Kan. – Cutting-edge biotech research laboratory Likarda has outgrown its space at the Bioscience & Technology Business Center (BTBC) on the KU Medical Center Campus and will move near the former Marion Laboratories campus in south Kansas City, Missouri, in October 2017. The move more than doubles the square footage of their former laboratory space, allowing Likarda to continue to scale up operations.

Likarda has occupied lab space at the BTBC since they were founded in May 2012. Since that time, their success as a pharmaceutical contract research organization and pioneer in animal health has seen the lab space grow to encompass the ground floor of the BTBC. As the race is constant to bring new drugs to market, pharmaceutical and nutraceutical companies and science entrepreneurs turn to contract research organizations (CROs) like Likarda to provide or supplement the research process.

Read More